We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

AI Outperforms Pathologists in Diagnosing Breast Cancer

By LabMedica International staff writers
Posted on 20 Dec 2017
A study comparing the ability of Artificial Intelligence (AI) algorithms with expert pathologists in detecting metastatic breast cancer in whole-slide images found that the machine learning outperformed the pathologists. The results of the study published in the Journal of the American Medical Association suggests that deep learning algorithms have the ability to improve diagnosis and could be used to help clinicians detect cancer in the clinic.

The study pitted 11 pathologists with time constraints and one pathologist without time constraints against seven deep learning algorithms in analyzing a training data set of whole-slide images – 110 with and 160 without verified nodal metastases. Out of the 49 test slides with metastatic disease, the pathologists found 31 on an average, while the pathologist allowed to work without time constraint correctly identified 46 out of 49 slides with cancer and 79 out of 80 slides without cancer.

Among the seven deep learning algorithms, the best algorithm performed significantly better in the whole-slide image classification task as compared to the pathologists working with time constraints. The mean performance of the top five algorithms was comparable with that of the single pathologist working without time constraints. However, at a mean of 0.0125 false-positives per normal whole-slide image, the performance of the best-performing algorithm was comparable with that of the single pathologist working without time constraint.

The research was led by Babak Ehteshami Bejnordi, Radboud University Medical Centre Nijmegen in the Netherlands. The researchers concluded that while the findings suggested the potential utility of deep learning algorithms for pathological diagnosis, it required further assessment in a clinical setting.


New
Gold Member
LEISHMANIA Test
LEISHMANIA ELISA
New
Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
RFID Tag
AD-302 M730
New
Urine Drug Test
Instant-view Propoxyphene Urine Drug Test

Latest Industry News

Bio-Rad to Acquire Digital PCR Developer Stilla Technologies

ABL Signs Know-How License and Transfer Agreement for Siemens’ Fast Track Diagnostics PCR Portfolio

Becton Dickinson to Spin Out Biosciences and Diagnostic Solutions Business



Sekisui Diagnostics UK Ltd.